1,393 results on '"Sundaram, Murali"'
Search Results
152. Osteoblastomatosis of bone. A benign, multifocal osteoblastic lesion, distinct from osteoid osteoma and osteoblastoma, radiologically simulating a vascular tumor
153. Spondyloarthropathy presenting at a young age: case report and review
154. New Applications and Techniques for Nanotube Superfiber Development
155. The incidence of imaging findings, and the distribution of skeletal lymphoma in a consecutive patient population seen over 5 years
156. Test yourself: index finger subungual pain
157. Ewing’s sarcoma of the humerus mimicking fibrous dysplasia on imaging and biological behavior
158. Creation of Functionally Graded Glass Channels by Electrochemical Discharge Machining Process: A Feasibility Study
159. Effects of Size Reduction on the Failure Mechanism of 3D Printed PLA+ Parts
160. Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.
161. Chondroblastoma of the hands and feet
162. Primary Ewing’s sarcoma of the vertebral column
163. Radiographic differentiation of enchondroma from low-grade chondrosarcoma in the fibula
164. Imaging features of low-grade central osteosarcoma of the long bones and pelvis
165. Fibrous dysplasia with cartilaginous differentiation (“fibrocartilaginous dysplasia”): a review, with an illustrative case followed for 18 years
166. 3 - Radiologic Evaluation of Soft Tissue Tumors
167. Anterior rim tibial plateau fractures and posterolateral corner knee injury
168. Mycobacterium marinum infections of the distal upper extremities: clinical course and imaging findings in two cases with delayed diagnosis
169. The distal semimembranosus complex: normal MR anatomy, variants, biomechanics and pathology
170. Vertebral chondroblastoma
171. Validation of the physicianʼs global assessment of psoriasis of the hands and/or feet as a clinical endpoint: P7039
172. Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis: P6690
173. Evaluation of factors associated with cumulative life course impairment using a novel patient reported outcome for patients with psoriasis: P6638
174. Incremental medical service costs associated with escalating methotrexate dosage versus switching to adalimumab in patients with psoriasis: P6648
175. Effect of adalimumab treatment on pruritus: A post-hoc analysis of the phase III, randomized REVEAL trial in patients with moderate to severe psoriasis: P6650
176. Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology: P6676
177. Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease: P6595
178. Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation: P6647
179. Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases: P6687
180. Patients’ experiences with hidradenitis suppurativa: A qualitative study of symptoms and impacts: P6668
181. Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis: P6674
182. Severe toxic osteoblastoma of the humerus associated with diffuse periostitis of multiple bones
183. Destructive spondyloarthropathy of the cervical spine in long-term hemodialyzed patients: a five-year clinical radiological prospective study
184. Electrical and Electrochemical Processes
185. Advances in Musculoskeletal Tumor Imaging
186. Contributors
187. Paget's Disease, Fibrous Dysplasia, Sarcoidosis, and Amyloidosis of Bone
188. Sex-specific differences in health-related quality of life in patients with moderate to severe psoriasis
189. Quality of life effects of psoriasis skin symptoms affecting different body regions
190. Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis
191. Impact of sustained robust response on patient-reported outcomes for adalimumab-treated patients with moderate to severe psoriasis: Subanalysis of REVEAL
192. Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event–free response versus etanercept
193. Further validation of the safe psoriasis control metric: A composite measure of benefit and risk in psoriasis treatment
194. Cost per responder with adalimumab versus ustekinumab treatment for moderate to severe psoriasis with suboptimal response to etanercept
195. Comparison of benefit–risk profiles with adalimumab versus etanercept treatment for moderate to severe psoriasis, stratified by weight
196. Approved adalimumab dosing regimen associated with greater efficacy and lower cost per responder compared with 40 mg every other week dosing without initial 80 mg dose: Analysis of outcomes from adalimumab psoriasis clinical trial database
197. Benefit–risk outcomes with adalimumab versus methotrexate for moderate to severe psoriasis during the first year of treatment
198. Adalimumab improves health-related quality of life and work productivity in patients with hidradenitis suppurativa: Results from a placebo-controlled phase II trial
199. Adalimumab reduces pain in patients with hidradenitis suppurativa: Results from a placebo-controlled phase II trial
200. Magnetic resonance imaging for solitary lesions of bone: when, why, how useful?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.